Related Experiment Video
Updated: Feb 17, 2026
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Stereotactic Body Radiation Therapy in Primary and Metastatic Liver Disease
Donatella Caivano1, Maurizio Valeriani2, Ivana Russo2
1CNAO, National Centre of Oncological Hadrontherapy, Pavia, Italy donatella.caivano@gmail.com.
Background/Aim:
The aim of this study was to investigate the treatment outcomes and toxicities in patients with liver disease treated by Stereotactic Body Radiation Therapy (SBRT).
Patients And Methods:
From 2007 to 2016, 43 patients with 58 lesions (6 primary and 37 metastatic liver tumors) were treated with SBRT.
Results:
Local Control was reached in 47 out of 58 (81%) treated lesions with 12 and 24-month rates of 81% and 74% respectively. The progression-free survival at 12 and 24 months was 42% and 36%, respectively. The disease specific survival at 12 and 24 months was 74% and 46% respectively. Median overall survival (OS) was 20 months and the rates of OS were 74% and 46% at 12 and 24 months respectively. Toxicity was very low consisting mainly of Grade 1 and 2.
Conclusion:
SBRT provides good local control for both primary and metastatic liver lesions, with minimal toxicity.
